ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "genomics"

  • Abstract Number: 433 • 2012 ACR/ARHP Annual Meeting

    Genome Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with Anti-TNF Medication. Results of the DREAM and Danbio Registries

    Marieke J.H. Coenen1, Masha Umicevic-Mirkov2, Hans Scheffer2, Sophine B. Krintel3, Sita H. Vermeulen4, Julia S. Johansen3, Wietske Kievit5, Mart A.F.J. van de Laar6, Piet L.C.M. van Riel5, Barbara Franke2 and Merete L. Hetland7, 1Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Human Genetics (855), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3DANBIO and Department of Rheumatology, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 4Human Genetics and Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 6Department of Rheumatology and DREAM registry, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, 7Copenhagen University Hospital Glostrup, Copenhagen, Denmark

    Background/Purpose: Patients with rheumatoid arthritis (RA)  rate pain relief as the highest priority in treatment outcome, and tumor necrosis factor inhibitors (anti-TNF) have proven very…
  • Abstract Number: 996 • 2012 ACR/ARHP Annual Meeting

    Genetic Predictors of Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results From the Treatment of Early Aggressive Rheumatoid Arthritis Trial

    Stella Aslibekyan1, Elizabeth Brown2, Richard J. Reynolds3, David T. Redden4, Sarah L. Morgan5, Joseph Baggott1, Jin Sha1, Larry W. Moreland6, James R. O'Dell7, Jeffrey R. Curtis8, S. Louis Bridges Jr.9 and Donna K. Arnett1, 1University of Alabama at Birmingham, Birmingham, AL, 2Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, 3Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Biostatistics, University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama Birmingham, Birmingham, AL, 6Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, 8Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, 9Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Methotrexate (MTX) has emerged as first-line therapy for early moderate to severe rheumatoid arthritis (RA), but individual variation in treatment efficacy and toxicity remains…
  • Abstract Number: 424 • 2012 ACR/ARHP Annual Meeting

    Influence of Pregnancy On Disease Activity-Associated Genes in Rheumatoid Arthritis

    Erik J. Peterson1, Shreyasee Amin2, Hatice Bilgic3, Emily Baechler Gillespie3, Jane E. Salmon4, Ann M. Reed5, Weihua Guan6 and Daniel L. Mueller1, 1Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, 2Division of Rheumatology, Mayo Clinic, Rochester, MN, 3University of Minnesota Medical School, Minneapolis, MN, 4Rheumatology, Hospital for Special Surgery, New York, NY, 5Rheumatology, Mayo Clinic, Rochester, MN, 6University of Minnesota School of Public Health, Minneapolis, MN

    Background/Purpose: Rheumatoid arthritis (RA) disease activity can often quiesce during pregnancy. Nevertheless, most women will experience a disease flare postpartum (PP). We hypothesized that changes…
  • Abstract Number: 997 • 2012 ACR/ARHP Annual Meeting

    Evidence of Novel Genetic Predictors of Methotrexate Efficacy in Rheumatoid Arthritis

    Stella Aslibekyan1, Maria I. Danila2, Jin Sha1, David T. Redden3, Richard J. Reynolds4, Elizabeth Brown5, Laura B. Hughes6, Molly S. Bray1, Sarah L. Morgan7, Larry W. Moreland8, James R. O'Dell9, Jeffrey R. Curtis10, Robert P. Kimberly11, Lindsey A. Criswell12, Robert M. Plenge13, S. Louis Bridges Jr.14 and Donna K. Arnett1, 1University of Alabama at Birmingham, Birmingham, AL, 2Med/Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, 3Biostatistics, University of Alabama at Birmingham, Birmingham, AL, 4Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, 6Med Div of Clin Imm & Rheum, University of Alabama at Birmingham, Birmingham, AL, 7University of Alabama Birmingham, Birmingham, AL, 8Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 9Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, 10Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, 11Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 12Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, 13Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 14Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Methotrexate (MTX), a disease-modifying anti-rheumatic drug used as first-line therapy in rheumatoid arthritis (RA), is characterized by considerable heterogeneity in individual treatment response. We…
  • Abstract Number: 409 • 2012 ACR/ARHP Annual Meeting

    Pathway Analysis of Genome-Wide Association Studies On Rheumatoid Arthritis

    Young Ho Lee1, Sung Jae Choi2, Jong Dae Ji2 and Gwan Gyu Song3, 1Internal Medicine, Rheumatology, Korea University Medical Center, Seoul, South Korea, 2Rheumatology, Korea University Medical Center, Seoul, South Korea, 3Div of Rheum, Dept of Int Med, Korea Univ College of Med, Seoul, South Korea

    Background/Purpose: Genome-wide association studies (GWASs) have been successfully used to identify novel common genetic variants that contribute to susceptibility to complex diseases, but individual GWASs…
  • Abstract Number: 998 • 2012 ACR/ARHP Annual Meeting

    Association Study of Genetic Risk Variants for Psoriasis in a Large Cohort of Psoriatic Arthritis, Psoriasis and Controls of the Spanish Population and Association with Relevant Clinical Subphenotypes

    J. D. Cañete1, Jose Luis Fernandez-Sueiro2, Raimon Sanmarti3, Jesus Rodriguez4, Jordi Gratacós5, Rubén Queiro6, Juan Carlos Torre-Alonso7, Jose Perez Venegas8, Santiago Muñoz-Fernandez9, Carlos Gonzalez10, Carlos Montilla11, Daniel Roig12, Alba Erra13, Isabel Acosta14, Antonio Fernández-Nebro15, Pedro Zarco16, Arnald Alonso17, María América López-Lasanta17, Antonio Julià17, Raül Tortosa17 and Sara Marsal18, 1Unitat d'Artritis, Servei de Reumatologia, Hospital Clínic de Barcelona,, Barcelona, Spain, 2Rheumatology Service, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, 3Rheumatology Service, Hospital Clínic of Barcelona, Barcelona, Spain, 4Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, 5Rheumatology Service, Hospital Parc Taulí, Sabadell (Barcelona), 6Rheumatology Service, Hospital Universitario Central de Asturias, Oviedo, Spain, 7Rheumatology Service, Hospital Monte Naranco, Oviedo, Spain, 8Rheumatology Service, Hospital del SAS de Jerez de la Frontera, Jerez De La Frontera, Spain, 9Rheumatology Service, Hospital Infanta Sofía, Madrid, Spain, 10Rheumatology Service, Hospital Gregorio Marañon, Madrid, Spain, 11Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, 12Rheumatology Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat- Barcelona, Spain, 13Rheumatology Service, Hospital San Rafael, Barcelona, Spain, 14Rheumatology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain, 15Rheumatology Service, Hospital Regional Universitario Carlos Haya, Málaga, Spain, 16Rheumatology Service, Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, 17Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 18Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain

    Background/Purpose: Psoriatic Arthritis (PsA) is a complex disease with a substantial genetic risk component (first-degree relative risk ~ 55). Recently, Genomewide Association Studies (GWAS) have…
  • Abstract Number: 313 • 2012 ACR/ARHP Annual Meeting

    Epigenetic Changes in Fibrosis and Myocyte Repair Genes May Contribute to Pathogenesis in Monozygotic Twins Discordant for Cardiac Manifestations of Neonatal Lupus

    Paula S. Ramos1, Timothy D. Howard2, Miranda C. Marion3, Satria Sajuthi4, Robert M. Clancy5, Jill P. Buyon6 and Carl D. Langefeld4, 1Department of Medicine, Medical University of South Carolina, Charleston, SC, 2Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, 3Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, 4Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 5Medicine, New York University School of Medicine, New York, NY, 6Department of Medicine, New York University School of Medicine, New York, NY

    Background/Purpose: Cardiac manifestations of neonatal lupus (cardiac-NL) which comprise conduction defects and cardiomyopathy, occur in fetuses exposed to maternal anti-Ro antibodies and carry a case…
  • Abstract Number: 999 • 2012 ACR/ARHP Annual Meeting

    Identification of New Epistatic Interactions with the HLA Region in the Genetic Etiology of Psoriasis and Psoriatic Arthritis

    Sara Marsal1, Juan D. Cañete2, Jose Luis Fernandez-Sueiro3, Raimon Sanmarti2, Jesus Rodriguez Moreno4, Jordi Gratacós5, Rubén Queiro6, Carlos Montilla7, Juan Carlos Torre-Alonso8, Jose Perez Venegas9, Santiago Muñoz-Fernández10, Carlos M. Gonzalez11, Daniel Roig12, Alba Erra13, Isabel Acosta1, Antonio Fernández-Nebro14, Pedro Zarco15, Arnald Alonso16, María América López-Lasanta16, Raül Tortosa16 and Antonio Julià16, 1Rheumatology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain, 2Rheumatology Service, Hospital Clínic of Barcelona, Barcelona, Spain, 3Rheumatology Service, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, 4Rheumatology Service, Hospital Universitario de Bellvitge., Barcelona, Spain, 5Rheumatology Service, Hospital Universitari Parc Taulí, Sabadell (Barcelona), Spain, 6Rheumatology Service, Hospital Universitario Central de Asturias, Oviedo, Spain, 7Rheumatology Service, Hospital Universitario de Salamanca, Salamanca, Spain, 8H. Monte Naranco, Oviedo, Spain, 9Rheumatology Service, Hospital del SAS de Jerez de la Frontera, Jerez De La Frontera, Spain, 10Unit Rheumatology, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes (Madrid), Spain, 11Rheumatology, Hospital Gregorio Maranon, Madrid, Spain, 12Rheumatology Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat- Barcelona, Spain, 13Rheumatology Service, Hospital San Rafael, Barcelona, Spain, 14Rheumatology Service, Hospital Regional Universitario Carlos Haya, Málaga, Spain, 15Rheumatology Service, Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, 16Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: Psoriatic Arthritis (PsA) is a complex disease and is present in ~11% in patients with Psoriasis (Ps). Recently, Genomewide Association Studies (GWAS) have expanded…
  • Abstract Number: 2548 • 2012 ACR/ARHP Annual Meeting

    Global Molecular Effects of Tocilizumab Therapy in Synovial Biopsies of Early Rheumatoid Arthritis Patients

    Julie Ducreux1, Adrien Nzeusseu Toukap2, Frédéric A. Houssiau1, Patrick Durez3 and Bernard Lauwerys3, 1Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, 2Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 3Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that is characterized by the presence of inflammatory cytokines, including interleukin-6 (IL-6). Here, we…
  • Abstract Number: 976 • 2012 ACR/ARHP Annual Meeting

    Effect of Interactions Between Validated Rheumatoid Arthritis Genetic Factors and Environmental Factors On Rheumatoid Arthritis Risk

    Chia-Yen Chen1, Linda T. Hiraki2, Susan Malspeis3, Jing Cui4, Bing Lu4, Robert M. Plenge5, Karen H. Costenbader4 and Elizabeth W. Karlson6, 1Department of Epidemiology, Harvard School of Public Health, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, 3Rheumatology, Brigham and Women's Hospital, Boston, MA, 4Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 6Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose:  Studies have shown associations between environmental factors and rheumatoid arthritis (RA) risk. Also, genome-wide association studies (GWAS) have identified genetic markers associated with RA…
  • Abstract Number: 2671 • 2012 ACR/ARHP Annual Meeting

    A Genome-Wide Association Study Establishes Muliple Susceptibility Loci for Sjögren’s Syndrome

    Christopher J. Lessard1, He Li2, Indra Adrianto3, John A. Ice3, Roland Jonsson4, Gabor G. Illei5, Maureen Rischmueller6, Gunnel Nordmark7, Xavier Mariette8, Corinne Miceli-Richard9, Marie Wahren-Herlenius10, Torsten Witte11, Michael T. Brennan12, Roald Omdal13, Patrick M. Gaffney3, James A. Lessard14, Wan-Fai Ng15, Nelson L. Rhodus16, Barbara M. Segal17, R. Hal Scofield18, Judith A. James19, Juan-Manuel Anaya20, John B. Harley21, Courtney G. Montgomery3 and Kathy Moser Sivils19, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway, 5Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD, 6Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, 7Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 8Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, 9Hopital Bicêtre, Le Kremlin Bicêtre, France, 10Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 11Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, 12Nidcr NIH, Carolinas Medical Center, Charlotte, NC, 13Department of Internal Medicine, Stavanger university Hospital, Stavanger, Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 14Valley Bone and Joint Clinic, Grand Forks, ND, 15Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle University, Newcastle, England, 16University of Minnesota, Minneapolis, MN, 17Rheumatology, Hennepin County Medical Center, Minneapolis, MN, 18Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 19Oklahoma Medical Research Foundation, Oklahoma City, OK, 20School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, 21Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH

    Background/Purpose: Sjögren’s syndrome (SS) is a common, clinically heterogeneous autoimmune disease characterized by exocrine gland dysfunction that involves both innate and adaptive immune responses. A…
  • Abstract Number: 2303 • 2012 ACR/ARHP Annual Meeting

    Confirmation of TNIP1 As a Susceptibility Locus for Systemic Sclerosis in a Large Multicentre Study

    Lara Bossini-Castillo1, Jose Ezequiel Martin2, Carmen Pilar Simeon3, Lorenzo Beretta4, Olga Y. Gorlova5, Madelon C. Vonk6, Patricia Carreira7, the Spanish Scleroderma Group8, Annemie Schuerwegh9, Alexandre Voskuyl10, Anna-Maria Hoffmann-Vold11, Roger Hesselstrand12, Annika Nordin13, Claudio Lunardi14, Jaap Van Laar15, Paul Shiels16, Ariane Herrick17, Jane Worthington18, Carmen Fonseca19, Christopher P. Denton19, Shervin Assassi20, Bobby P.C. Koeleman21, Maureen D. Mayes22, T.R.D.J. Radstake23 and Javier Martin1, 1Immunology, Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain, 2Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 3Servicio de Medicina Interna, Hospital Valle de Hebron, Barcelona, Spain, 4Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 5Department of Epidemiology, UT M. D. Anderson Cancer Center, Houston, TX, 6Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 7Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 8Granada, Spain, 9Leids Univ Medisch Centrum, Leiden, Netherlands, 10Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 11Rheumatology, Oslo University Hospital, Oslo, Norway, 12Rheumatology, Lund University, Lund, Sweden, 13Department of Rheumatology, Karolinska Institute, Stockholm, Sweden, 14Department of Medicine, Università degli Studi di Verona, Verona, Italy, 15Rheumatology, Leiden University Hospital, Leiden, Netherlands, 16University of Glasgow, Glasgow, United Kingdom, 17Musculoskeletal Research Group, University of Manchester, Salford, United Kingdom, 18Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 19Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 20Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 21Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, 22Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 23Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Systemic sclerosis or scleroderma (SSc) is a complex autoimmune disorder that affects the connective tissue causing fibrosis in the skin and different internal organs.…
  • Abstract Number: 978 • 2012 ACR/ARHP Annual Meeting

    A Genome-Wide Interaction Study with Smoking Suggests New Risk Loci for Two Different Subsets of Rheumatoid Arthritis; Results From Swedish Epidemiological Investigation of Rheumatoid Arthritis Study

    Xia Jiang1, Henrik Källberg1, Leonid Padyukov2, Lars Klareskog3 and Lars Alfredsson1, 1Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 3Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is believed to have a multifactorial etiology, involving both genetic and environmental components, and can be divided into two major subsets…
  • Abstract Number: 2654 • 2012 ACR/ARHP Annual Meeting

    Genome-Wide Association Study of Methotrexate Response Identifies Novel Genes in a Large Cohort of European Juvenile Idiopathic Arthritis Cases

    Joanna Cobb1, Erika Cule2, Halima Moncrieffe3, Edward Flynn4, Anne Hinks1, Fiona Patrick3, Laura Kassoumeri3, Simona Ursu5, Maja Bulatovic6, Marek Bohm7, Bertrand D. van Zelst8, Pavla Dolezalova9, Robert De Jonge8, Nico M. Wulffraat6, Stanton Newman10, Maria de Iorio11, Lucy R. Wedderburn3 and Wendy Thomson1, 1Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 2Department of Epidemiology and Biostatistics, Imperial College London, United Kingdom, 3Institute of Child Health, University College London, London, United Kingdom, 4Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, 5Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 6Paediatric Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, 7First Faculty of Medicine and General Faculty Hospital, Prague, Czech Republic, 8Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, 9Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, 10School of Community & Health Sciences, City University London, London, United Kingdom, 11Department of Statistical Sciences, University College London, London, United Kingdom

    Background/Purpose: The drug methotrexate (MTX) is the first line treatment for many children with Juvenile Idiopathic Arthritis (JIA). Only 45% of children treated with MTX…
  • Abstract Number: 2304 • 2012 ACR/ARHP Annual Meeting

    Differential Association of IRAK1 and MECP2 with Specific Systemic Sclerosis Phenotypes

    F. David Carmona1, M.C. Cénit1, L.M. Díaz-Gallo1, Carmen P. Simeón2, Patricia Carreira3, the Spanish Scleroderma Group4, Nicolas Hunzelmann5, Gabriela Riemekasten6, Torsten Witte7, Alexander Kreuter8, Jörg HW Distler9, Paul Shiels10, Jacob M. van Laar11, Annemie Schuerwegh12, Madelon C. Vonk13, Alexandre Voskuyl14, Carmen Fonseca15, Christopher Denton16, Ariane Herrick17, Frank C. Arnett18, Filemon K. Tan18, Shervin Assassi18, T.R.D.J. Radstake19, Maureen D. Mayes18 and Javier Martin1, 1Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas, Armilla (Granada), Spain, 2Department of Internal Medicine, Hospital Valle de Hebron, Barcelona, Spain, 3Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 4Granada, Spain, 5Department of Dermatology, University of Cologne, Cologne, Germany, 6Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, 7Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, 8Department of Dermatology, Venereology, and Allergologie, HELIOS St. Elisabeth Hospital, Oberhausen, Germany, 9Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 10University of Glasgow, Glasgow, United Kingdom, 11Newcastle University, Musculoskeletal Research Group, Newcastle, United Kingdom, 12Leids Univ Medisch Centrum, Leiden, Netherlands, 13Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 14Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 15Department of Rheumatology, Royal Free Hospital, London, United Kingdom, 16Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 17Musculoskeletal Research Group, University of Manchester, Salford, United Kingdom, 18Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 19Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Systemic sclerosis (SSc) is a fibrotic autoimmune disease that represents a clear example of a sex biased immune disorder. The X-chromosome gene IRAK1 has…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology